Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349140 · ClinicalTrials.gov registry record · Phase 1
EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01349140 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 14 participants.
The verdict
NCT01349140, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
EXPAREL™, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an investigational extended-duration formulation of the local anesthetic bupivacaine, on both motor and sensory block when applied in a fixed volume adjacent to the femoral nerve.
Interventions
- DRUG SKY0402
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01349140
The ClinicalTrials.gov registry entry for NCT01349140 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SKY0402 is the first listed.
NCT01349140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01349140 about?
NCT01349140 is a clinical study titled "EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks". EXPAREL™, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an investigational extended-duratio...
What is the current status of trial NCT01349140?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-02. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01349140?
The interventions under investigation include: SKY0402 (DRUG).
Who is sponsoring clinical trial NCT01349140?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.